Novartis AG vs S&P Global Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while S&P Global Inc trades at $431.27 (market cap $132.71B). The key difference: Novartis AG is far larger — about 2.2× S&P Global Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | SPGI | |
|---|---|---|
Market Cap | $290.25B | $132.71B |
Sector | Health | Financials |
52-Week High | $168.62 | $534.79 |
52-Week Low | $113.50 | $370.42 |
Enterprise Value | $330.27B | $144.68B |
Dividend Yield | 3.17% | 0.87% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →